GLUE: Monte Rosa starts Phase 2 study of MRT-6160
GLUE-linked disclosure says Monte Rosa Therapeutics has initiated a Phase 2 clinical study for its VAV1-directed molecular glue degrader MRT-6160 (DDY391).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.